To comply with applicable regulation in Denmark, product-related media releases are removed from our website within three weeks of publication. They are available upon request. Please contact us here. News Category AllArticles of AssociationCompany AnnouncementsMedia Releases Year All202420232022202120202019 Dec 11, 2024 at 2:21 PM CET Genmab to Hold 2024 R&D Update and ASH Data Review Meeting Dec 09, 2024 at 6:00 PM CET Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Download Dec 08, 2024 at 5:00 PM CET Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis Download Dec 08, 2024 at 1:12 AM CET Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Download Dec 04, 2024 at 2:44 PM CET Genmab A/S has published its Articles of Association Download Dec 03, 2024 at 10:35 PM CET Capital Increase in Genmab as a Result of Employee Warrant Exercise Download Dec 03, 2024 at 1:08 PM CET Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Download Nov 27, 2024 at 5:17 PM CET Genmab A/S has published its Articles of Association Download Nov 25, 2024 at 5:06 PM CET Genmab to Present at Citi’s Global Healthcare Conference Download Nov 21, 2024 at 8:48 PM CET Grant of Restricted Stock Units and Warrants to Employees in Genmab Download Nov 06, 2024 at 5:02 PM CET Genmab Announces Financial Results for the First Nine Months of 2024 Download Nov 05, 2024 at 7:11 PM CET Genmab to Present at Jefferies London Healthcare Conference Download Oct 15, 2024 at 12:26 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 Download Oct 04, 2024 at 7:56 PM CEST Major Shareholder Announcement Download Oct 01, 2024 at 3:11 PM CEST Genmab A/S has published its Articles of Association Download Sep 26, 2024 at 9:18 PM CEST Grant of Restricted Stock Units and Warrants to Employees in Genmab Download Sep 11, 2024 at 8:30 PM CEST Genmab A/S has published its Articles of Association Sep 10, 2024 at 10:07 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download Aug 26, 2024 at 6:26 PM CEST Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference Download Aug 19, 2024 at 8:00 PM CEST TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Download Aug 16, 2024 at 3:00 PM CEST Genmab Announces Changes to its Executive Committee Download Aug 14, 2024 at 4:23 PM CEST Genmab A/S has published its Articles of Association Download Aug 13, 2024 at 8:53 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Download Aug 13, 2024 at 8:51 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download Aug 08, 2024 at 5:03 PM CEST Genmab Announces Financial Results for the First Half of 2024 Download
Dec 09, 2024 at 6:00 PM CET Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Download
Dec 08, 2024 at 5:00 PM CET Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis Download
Dec 08, 2024 at 1:12 AM CET Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Download
Dec 03, 2024 at 10:35 PM CET Capital Increase in Genmab as a Result of Employee Warrant Exercise Download
Dec 03, 2024 at 1:08 PM CET Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Download
Nov 21, 2024 at 8:48 PM CET Grant of Restricted Stock Units and Warrants to Employees in Genmab Download
Nov 06, 2024 at 5:02 PM CET Genmab Announces Financial Results for the First Nine Months of 2024 Download
Oct 15, 2024 at 12:26 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 Download
Sep 26, 2024 at 9:18 PM CEST Grant of Restricted Stock Units and Warrants to Employees in Genmab Download
Sep 10, 2024 at 10:07 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download
Aug 26, 2024 at 6:26 PM CEST Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference Download
Aug 19, 2024 at 8:00 PM CEST TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Download
Aug 13, 2024 at 8:53 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Download
Aug 13, 2024 at 8:51 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download